Cambridge Biotech Corp. (NASDAQ:CBCX) agreed to licenseDynaGen Inc.'s (NASDAQ:DYGN) technology for developingtuberculosis and other mycobacterial diagnostic products.DynaGen of Cambridge, Mass., will supply its antigen toCambridge Biotech of Worcester, Mass., which will then produceserology tests in the EIA microwell format, as well as in rapidslide immunoassays. Cambridge Biotech will distribute theproducts worldwide. The market for TB testing devices couldexceed $20 million by 1994, with an annual growth ratethereafter of 9 percent..

(c) 1997 American Health Consultants. All rights reserved.

No Comments